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abstract
Apart from their administrative purpose, death certificate 
data are a major means of identifying public health problems 
and evaluating the effectiveness of programs developed to deal 
with these public health problems.  The inaccuracies in death 
certification are well documented in the international literature. 
This study aimed to estimate the accuracy in cancer death 
certification locally, as well as present common types of errors in 
order to create educational awareness.    
introduction
Without health data, governments and other organisations 
cannot accurately target resources to prevent deaths and diseases, 
and have no way to measure whether their efforts are working.1 
Mortality data obtained from information recorded on the death 
certificate is one of the oldest sources of health data. Published 
mortality data for Malta, by cause of death are available since 1872. 
These were produced in the form of a fortnightly report published 
by the Chief Police Physician. Annual reports after 1896 were 
published by the Chief Government Medical Officer.
Mortality data is a source of information used:
1. To monitor trends and patterns in disease;
2. To guide health promotion, resource allocation,   
service planning and priority determination;
3. For research and epidemiology; and
4. For administrative purposes including settlement   
of estates, welfare and pension entitlements and   
insurance payment.2   
Mortality statistics are mainly based on the ‘underlying cause 
of death’ which is defined as “(a) the disease or injury which 
initiated the train of morbid events leading directly to death, or 
(b) the circumstances of the accident or violence which produced 
the fatal injury”.3 This is because from the standpoint of prevention 
of death, it is necessary to break the chain of events or to effect a 
cure at some point. The most effective public health objective is to 
prevent the precipitating cause from operating. 
For this reason, section 16 of the Medical Death Certificate is 
divided into two parts with part I relating to the train of events 
leading directly to death, and part II concerns unrelated but 
contributory conditions. The condition recorded on the lowest 
used line of part I of the certificate is usually the underlying cause 
of death used for tabulation, if the death certificate is completed 
accurately.
Despite the importance of accurate death certification, errors 
are common. International studies report inaccuracies in death 
certificates to be 20-65%.4,5 In a previous local study (by the author, 
unpublished), it was found that 37% of death certificates reviewed 
were found to have a major error which means that coders had 
difficulty in choosing the correct underlying cause of death. The 
variable which was most significantly associated with a major 
error rate was age of the deceased.
aiM 
The aim of the study was to review all death certificates in 
2013 and estimate the accuracy in cancer death certification. 
The common types of errors are presented in order to create 
educational awareness.    
MEthodology
All death certificates of deaths registered during 2013 were 
reviewed and the main cause of death according to the certifier 
was extracted. Where the main cause of death was certified to 
be cancer, the death certificate was reviewed and additional 
information obtained by linking with the National Cancer 
Registry, seeking histology and radiological information from 
ISOFT and accessing the electronic case summary of the patient 
to confirm or otherwise the cancer and the underlying cause of 
death. 
rEsults
In all there were 888 death certificates which were classified 
as a cancer death i.e. a particular cancer was recorded by the 
certifier as the main or underlying cause of death. Of these, 796 
certificates or 89.6% were confirmed to be correct. As seen in 
table 1 below, the error rate increased with age of the deceased. 
This is attributed to the fact that often in the elderly, competing 
causes may exist and the certifier may be unsure what was the 
main or underlying cause of death.
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Figure 1: Example of a completed medical section of the death certificate
Table 1:  Number and % of major errors in cancer death certification
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The percentage of incorrectly completed death certificates 
involving a cancer as a main cause was higher in death 
certificates certified by general practitioners compared to 
those certified by hospital doctors (14% versus 10%). This 
can be generally attributed to less accurate information being 
available to the general practitioner versus the hospital doctor. 
Furthermore, the proportion of death certificates certified by 
general practitioner increases in the elderly and decreases for 
hospital doctors. 
  The main errors identified were:
1. Conflicting causes of death written in part I of section 16 
e.g. Metastasis  
 Ca Bladder and Ca Colon 
2. Conflicting causes of death and wrong sequence of events 




 Diabetes mellitus  
3. Wrong cancer written down on the death certificate
•	 “Metastasis” without identification of primary site should 
only be written when there is no known primary site and 
this should be stated.
•	 When there is metastasis to the lung, the certifier should 
write “Metastasis to the lung with unknown primary”. 
In this case, reporting “Carcinoma Lung” is incorrect 
as the coder would not know if it is a primary or due to 
metastasis.
•	 “Carcinoma oesophagus” should not be written when the 
primary site of the carcinoma is the stomach.
•	 When writing “liver cancer” one should always specify 
whether it is primary or secondary. 
4. No evidence of cancer
In a few of the certificates reviewed, especially in elderly 
persons, there was mention of a cancer with no evidence found 
by the coder.
A number of other minor errors have also been identified 
which include absence of time intervals between onset and death 
and lack of specificity about the tumour. E.g. “Adeno-carcinoma 
of the sigmoid colon” should be written rather than “cancer of 
the colon”; “Left frontal lobe primary malignant tumour of brain 
consistent with astrocytoma” should be written instead of “brain 
tumour”.
discussion and conclusions
In a previous local study (by the author, unpublished), 
high levels of agreement between the certifier and 
the medical notes were found for neoplasms (92%), 
cerebrovascular disease (92%) and chronic lower respiratory 
diseases (86%).  Lower levels of agreement were found for 
Ischaemic heart disease (78%),  pneumonia (58%) and 
diabetes mellitus (31%).    
The reported rate for neoplasms (92%) is similar to that 
found in this study (89.6%) and highlights the fact that 
deaths from neoplasms tend to be more straightforward than 
other conditions which involve multiple co-morbidity.
Often physicians enter correct diagnoses on the 
death certificate in an incorrect fashion. The reasons for 
this are many, but most commonly involve problems 
in distinguishing among the underlying cause of death, 
the immediate cause of death, the manner of death, and 
conditions contributing to death.6
Age is often associated with increase in major errors. 
Aging is often accompanied by the development of 
degenerative and chronic processes that affect many body 
systems. The question then arises as to which of the several 
co-existing conditions caused death. The clinician may 
logically say that none of the diseases singly, but rather 
a combination of conditions, caused the patient’s death.7 
However it must be remembered that the attending 
physician is the one individual best able to prioritize the 
medical history in order to determine, in his or her best 
judgment, what disease process initiated the sequence of 
events leading to death.6
Doctors may find difficulty in completing a death 
certificate and distinguishing among the underlying cause 
of death, the immediate cause of death, the manner of 
death and conditions contributing to death. The increase 
in availability of electronic patient health data to doctors, 
especially general practitioners, is an important tool for 
reporting more specific information e.g. exact type of cancer. 
While ad hoc training into the completion of the 
death certificate has been undertaken several times by the 
Directorate for Health Information and Research, death 
certificate completion is not included in any structured 
training programme for post-graduate doctors and new 
teaching tools need to be developed to reach as many 
doctors as possible in an on-going fashion.  
Which cancer is responsible 
for the metastasis?
Which direct sequence of events lead 
to the death of the patient? All other 
conditions should be put in part II
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